Carl Awh, MD
Retina Specialist · Nashville, TNNPI 1386729085
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $852,313 of the $1,281,361 with a category attached, or 66.5%. 28 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 36.7% of the total. Among retina specialist clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $5005.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$471K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$410K
- Ocular Therapeutix, Inc.$105K
- US Retina LLC$67K
- Genentech USA, Inc.$59K
- F. Hoffmann-la Roche AG$44K
- plus $125K from 22 others
Across 751 payments — averaging $11,233 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$6.4M
- Ocular Therapeutix, Inc.$1.3M
- Apellis Pharmaceuticals, Inc.$552K
- Astellas Pharma Global Development$66K
- F. Hoffmann-la Roche AG$56K
- AbbVie$9K
What the payments were for
- Royalty or licence$852,31367%
- Consulting fees$255,44320%
- Speaking & faculty fees$44,8724%
- Travel & lodging$26,1602%
- Food & beverage$7,6921%
- Education$5830%
- Ownership interest$29,0472%
- Other$65,2515%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 36 | $470,590 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 24 | $410,309 |
| Ocular Therapeutix, Inc. | 12 | $104,908 |
| US Retina LLC | 7 | $67,057 |
| Genentech USA, Inc. | 49 | $59,308 |
| F. Hoffmann-la Roche AG | 16 | $44,090 |
| Genentech, Inc. | 21 | $28,765 |
| Glaukos Corporation | 1 | $27,241 |
| Amgen | 9 | $23,814 |
| Roche Products Limited | 4 | $22,891 |
| Katalyst Surgical, LLC | 8 | $9,662 |
| Novartis | 5 | $4,592 |
| AbbVie(2 entities) | 12 | $2,660 |
| Carl Zeiss Meditec, Inc. | 3 | $1,483 |
| Dutch Ophthalmic Research Center (international) B.v. | 5 | $1,083 |
| Regeneron Healthcare Solutions, Inc. | 10 | $851 |
| Astellas Pharma US Inc | 8 | $549 |
| Harrow Eye, LLC | 3 | $458 |
| Apellis Pharmaceuticals, Inc. | 6 | $236 |
| Dutch Ophthalmic, USA | 1 | $140 |
| Coherus Oncology, Inc. | 1 | $134 |
| Neurotech Pharmaceuticals, Inc. | 1 | $125 |
| Biogen | 2 | $118 |
| Alimera Sciences, Inc. | 6 | $115 |
| Eyepoint US, Inc. | 3 | $72 |
| Iridex Corporation | 1 | $71 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Regeneron | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPHTHALMIC INSTRUMENTS$843,401
- SUSVIMO$70,891
- Lucentis$47,790
- Mitosol$27,241
- PAVBLU$18,751
- 20ga Dex NanoTapered Awh Forceps$5,518
- STELLARIS PC$4,632
- BEOVU$4,300
- STELLARIS ELITE$1,758
- OZURDEX$1,700
- QUATERA 700$1,425
- CALLISTO eye$1,425
- CIRRUS HD-OCT$1,425
- CIRRUS 6000 with AngioPlex$1,425
- EVA, combined machine$1,190
- TISSUEBLUE$1,190
- SURGICAL MISC$750
- EYLEA$739
- VABYSMO$666
- DEXTENZA$594
How this compares
$1,281,361 in reported general payments places this provider in the 95th percentile of 58 retina specialist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 24 | $8,807 |
| Prednisolone Acetate | 147 | $6,011 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 79 | $4,520 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $4,272 |
| Bromfenac Sodium | 20 | $2,433 |
| Ketorolac Tromethamine | 79 | $1,482 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $1,395 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 40 | $590 |
| Atropine Sulfate | 12 | $450 |
| Latanoprost | 41 | $374 |
| Timolol Maleate | 39 | $369 |
| Brimonidine Tartrate | 16 | $220 |
| Ciprofloxacin Hcl | 12 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $410,309 | $8,80724 claims |
| AbbVieCombigan | $2,660 | $4,27216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 58 retina specialist providers in Tennessee.
Other retina specialist in Nashville
- Peter SonkinNashville$949K
- Brandon BusbeeNashville$566K
- Eric SchneiderNashville$134K
- David ReichsteinNashville$114K
- Akshay ThomasNashville$108K
- Franco RecchiaNashville$72K
- Everton ArrindellNashville$39K
- Roy WallaceNashville$19K
- Kenneth MoffatNashville$17K
- Brigid MarshallNashville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.